Cholangiocarcinoma News and Research

RSS

'Mismatch repair' genetic defects drive cancer patient's response to immunotherapy drugs

In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called 'mismatch repair' genetic defects, scientists at Johns Hopkins Medicine and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that half of the patients respond to an immunotherapy drug called pembrolizumab.

9 Jun 2017

Genetic sequencing could help direct treatment for 72% of advanced cancer patients

A new analysis finds that nearly three-quarters of 500 patients with advanced cancer could be referred to a potential targeted treatment based on the results of a comprehensive analysis of their tumor's genetic landscape.

2 Jun 2017

Researchers identify novel gene critical to development of lung and pancreatic cancer

Researchers at the Center for Applied Medical Research of the University of Navarra have identified a critical gene, FOSL1, in the development of lung and pancreatic cancer.

22 Feb 2017

Regular aspirin use may help reduce risk of bile duct cancer

Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study. The findings, which are published in the journal Hepatology, indicate that additional research on the potential of aspirin for preventing bile duct cancer is warranted.

27 Apr 2016

Aspirin use linked with reduced risk of developing bile duct cancer

A team of current and former Mayo Clinic researchers has discovered that aspirin use is associated with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma. The results are published in Hepatology.

20 Apr 2016

Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.

1 Feb 2016

CCF approved for Eugene Washington Engagement Award by PCORI to support upcoming conference

The Cholangiocarcinoma Foundation has been approved for a Eugene Washington Engagement Award by the Patient-Centered Outcomes Research Institute to support its 2016 Annual Conference on February 3-6 in Salt Lake City.

26 Jan 2016

Findings could offer doctors new method to diagnose pancreatic cancer earlier in patients

By collecting samples from the portal vein--which carries blood from the gastrointestinal tract, including from the pancreas, to the liver--physicians can learn far more about a patient's pancreatic cancer than by relying on peripheral blood from a more easily accessed vein in the arm.

23 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

Researchers develop multiplexed screening approach to study cancer development in mice

In a novel use of the CRISPR/Cas9 system, which can be deployed to switch genes off, researchers from Germany, the UK and Spain have developed a multiplexed screening approach to study and model cancer development in mice. The scientists mutated genes in the adult mouse liver uncovering their cancer-causing roles and determining which combinations of genes cooperate to cause liver cancer.

27 Oct 2015

Cancer-causing parasitic worm may help patients recover from wounds, say JCU scientists

It's short, ugly and deadly. But James Cook University scientists have found a cancer-causing, parasitic worm could help patients recover from their wounds.

22 Oct 2015

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer.

1 Sep 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

Delcath Systems achieves record quarterly product revenue in Q2 2015

5 Aug 2015

Study points to new treatment strategies for liver cancer

A new study by researchers at Sanford Burnham Prebys Medical Discovery Institute, the National Cancer Institute, and the Chulabhorn Research Institute has found that blocking the activity of a key immune receptor, the lymphotoxin-beta receptor (LTβR), reduces the progression of liver cancer.

25 Jul 2015

Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announced today that the U.S. Food and Drug Administration Office of Orphan Products Development has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma.

20 Jul 2015

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).

13 Jul 2015

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Foundation Medicine, Inc. today presented new data including promising clinical outcomes underscoring the importance of integrating comprehensive genomic profiling with FoundationOne® into clinical oncology care for the treatment of biliary tract cancers.

2 Jun 2015

CHEMOSAT treatment of UM patients with hepatic metastases highlighted at ASCO 2015

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that results of a large, European single-center experience of the treatment of uveal melanoma patients with hepatic metastases with the Delcath Hepatic CHEMOSAT® Delivery System, were highlighted in an on-line abstract at the American Society of Clinical Oncology Annual Meeting 2015.

1 Jun 2015

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.

7 Apr 2015